- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 879491, 5 pages
Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease
1Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
2Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
3Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, 3-1 North 33-jou East 14-chome East Ward, Sapporo, Hokkaido 065-0033, Japan
Received 16 July 2013; Revised 19 October 2013; Accepted 20 October 2013
Academic Editor: Hidekazu Kuramochi
Copyright © 2013 Aki Sakatani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- O. Bernell, A. Lapidus, and G. Hellers, “Risk factors for surgery and postoperative recurrence in Crohn's disease,” Annals of Surgery, vol. 231, no. 1, pp. 38–45, 2000.
- S. B. Hanauer, B. G. Feagan, G. R. Lichtenstein et al., “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial,” The Lancet, vol. 359, no. 9317, pp. 1541–1549, 2002.
- P. Rutgeerts, B. G. Feagan, G. R. Lichtenstein et al., “Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease,” Gastroenterology, vol. 126, no. 2, pp. 402–413, 2004.
- B. G. Feagan, R. Panaccione, W. J. Sandborn et al., “Effects ofadalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM Study,” Gastroenterology, vol. 135, no. 5, pp. 1493–1499, 2008.
- J.-F. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007.
- S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–332, 2006.
- G. R. Lichtenstein, S. Yan, M. Bala, M. Blank, and B. E. Sands, “Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease,” Gastroenterology, vol. 128, no. 4, pp. 862–869, 2005.
- F. Schnitzler, H. Fidder, M. Ferrante et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort,” Gut, vol. 58, no. 4, pp. 492–500, 2009.
- J. K. Bhatia, B. I. Korelitz, G. Panagopoulos et al., “A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone,” Journal of Clinical Gastroenterology, vol. 41, no. 7, pp. 677–681, 2007.
- M. Regueiro, W. Schraut, L. Baidoo et al., “Infliximab prevents Crohn's disease recurrence after ileal resection,” Gastroenterology, vol. 136, no. 2, pp. 441.e1–450.e1, 2009.
- A. Dignass, G. Van Assche, J. O. Lindsay et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 28–62, 2010.
- G. D'Haens, F. Baert, G. van Assche et al., “Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial,” The Lancet, vol. 371, no. 9613, pp. 660–667, 2008.
- D. W. Jones and S. R. G. Finlayson, “Trends in surgery for crohn's disease in the era of infliximab,” Annals of Surgery, vol. 252, no. 2, pp. 307–312, 2010.
- E. Domènech, Y. Zabana, E. Garcia-Planella et al., “Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 2, pp. 233–239, 2010.
- S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; preliminary report on a therapeutic trial,” British Medical Journal, vol. 2, no. 4884, pp. 375–378, 1954.
- R. W. Summers, D. M. Switz, and J. T. Sessions Jr., “National cooperative Crohn's disease study: results of drug treatment,” Gastroenterology, vol. 77, no. 4, pp. 847–869, 1979.
- H. Malchow, K. Ewe, and J. W. Brandes, “European cooperative Crohn's disease study (ECCDS): results of drug treatment,” Gastroenterology, vol. 86, no. 2, pp. 249–266, 1984.
- G. R. Greenberg, B. G. Feagan, F. Martin et al., “Oral budesonide for active Crohn's disease,” The New England Journal of Medicine, vol. 331, no. 13, pp. 836–841, 1994.
- M. Campieri, A. Ferguson, W. Doe, T. Persson, and L.-G. Nilsson, “Oral budesonide is as effective as oral prednisolone in active Crohn's disease,” Gut, vol. 41, no. 2, pp. 209–214, 1997.
- O. Ø. Thomsen, A. Cortot, D. Jewell et al., “A comparison of budesonide and mesalamine for active Crohn's disease,” The New England Journal of Medicine, vol. 339, no. 6, pp. 370–374, 1998.
- D. H. Present, B. I. Korelitz, and N. Wisch, “Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study,” The New England Journal of Medicine, vol. 302, no. 18, pp. 981–987, 1980.
- S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman, “A controlled double blind study of azathioprine in the management of Crohn's disease,” Gut, vol. 37, no. 5, pp. 674–678, 1995.
- J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010.